Pluripotent stem cell derived hepatocytes for liver failure (PUSH for LIFE)
Pluripotent stem cell derived hepatocytes for liver failure (PUSH for LIFE)
批准号:
MR/Z503940/1
负责人:
Tamir Rashid
金额:
$31.33万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2024
资助国家:
英国
项目状态:
未结题
起止时间:
2024 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Liver disease is on the rise. Three quarters of patients are diagnosed at a stage when it is too late for lifestyle changes or medical intervention to make a difference. This results in over 3,000 hospitalized cases and over 40 deaths from liver failure every day in the UK alone. To date, the only cure for a failing liver is to replace the organ with a new one, a procedure called liver transplantation. Unfortunately, we simply do not have enough donor organs to meet the surging demands of patients. Despite performing over 1,000 liver transplants each year, there are still more than 300 people on the transplant waiting list at any one time.Hepatocytes derived from induced pluripotent stem cells (iPSC-Heps) represent a potentially curative alternative, that could replace the need for transplant. We propose to deliver alginate encapsulated iPSC-Heps into the abdomen of patients with liver failure to serve as an auxiliary, short-term liver tissue. In this way, patients will be 'bridged' over the period during which their livers are not working properly until the point at which their liver has sufficiently regenerated to function unaided again or until the point at which a donor organ becomes available. The principle of bridging patients using cell therapy in this way has already been successfully demonstrated in eight patients with cadaveric donor derived primary human hepatocytes (PHH) (Dhawan et al. J. Hepatol. 2020). Due to the scarcity and unpredictable quality of donor PHH, this source of hepatocytes does not however represent a viable long-term solution to address the growing, global unmet medical needs of liver failure. Instead of using PHH therefore, we instead propose to use hepatocytes made from iPSCs. To realise this ambition, we now need to convert our academic iPSC-Hepatocyte generation protocol into a GMP-compliant manufacturing process that allows for the scalable generation of billions of iPSC-Heps which are suitable for patient use.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Manipulation of niche signals to advance cell therapies for liver disease
-
批准号:MR/L006537/1
-
项目类别:Fellowship
-
资助金额:$150.82万
-
财政年份:2014
-
负责人:Tamir Rashid
-
依托单位:
国内基金
海外基金
登录
查看更多内容
LIPUS促进微环境巨噬细胞释放CCL2诱导尿道周围平滑肌祖细胞定植与分化的机制研究
-
批准号:82370780
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:夏术阶
-
依托单位:
骨髓抑制再生单个核细胞移植通过调节线粒体功能在脑缺血再灌注损伤中的神经保护机制研究
-
批准号:82371301
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:李轶
-
依托单位:
血管内皮细胞源性的外泌体通过Notch信号通路增强肿瘤细胞可塑性的机制研究
-
批准号:32100627
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:张宇
-
依托单位:
哺乳动物新生期心肌细胞增殖及其调控机制研究
-
批准号:32100592
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:蒲文娟
-
依托单位:
LMNA基因R527C纯合突变儿童早老症干细胞功能异常及分子机理研究
-
批准号:32100603
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:周焱
-
依托单位:
PGCLCs介导小鼠多能干细胞始发态向原始态转变的机制研究
-
批准号:32100594
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:周纯华
-
依托单位:
NRF2/MFN2/ERS信号异常促进ADSCs衰老和肥大型肥胖皮下脂肪组织胰岛素抵抗的机制研究
-
批准号:32000511
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:方佳
-
依托单位:
骨髓干细胞分泌因子KIAA1199对骨和脂肪分化以及代谢的调控
-
批准号:32060155
-
项目类别:地区科学基金项目
-
资助金额:35.0万元
-
批准年份:2020
-
负责人:陈琍
-
依托单位:
线粒体功能对涡虫干细胞命运决定调控机制的研究
-
批准号:32000498
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:高充
-
依托单位:
m6A识别蛋白YTHDFs在体细胞重编程中的调控作用及机制研究
-
批准号:32000501
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:杨雪洁
-
依托单位: